Stock Markets May 7, 2026 03:03 PM

Biotech Funds Post $1.5 Billion Withdrawals in Latest Week, Raymond James Says

Sector records second straight week of net redemptions even as breadth metrics edge higher

By Avery Klein

Healthcare and biotech-focused mutual funds and ETFs experienced net outflows totaling $1.5 billion for the week ending Wednesday, according to Raymond James. The withdrawals amounted to a 1.53% reduction in assets across 130 funds that collectively manage roughly $99.5 billion. Year-to-date net outflows stand at $1.98 billion, and this marked the second consecutive week of redemptions. The breadth ratio rose to 0.48 from 0.45 the prior week; Raymond James notes historical rallies tied to low breadth readings, and observed that the breadth ratio had been 0.28 on July 16 while the Nasdaq Biotechnology Index has climbed about 36% since that date.

Biotech Funds Post $1.5 Billion Withdrawals in Latest Week, Raymond James Says

Key Points

  • Biotech and healthcare funds recorded $1.5 billion of net outflows for the week ending Wednesday, a 1.53% fall across 130 funds managing about $99.5 billion.
  • This week marks the second straight week of redemptions, bringing year-to-date net outflows to $1.98 billion, impacting fund managers and investor allocations within the healthcare and biotech sectors.
  • The breadth ratio rose to 0.48 from 0.45; Raymond James highlights that a breadth reading near 0.3 has historically preceded average six-month rallies of 17.5% in the biotech sector, and notes the breadth was 0.28 on July 16 while the Nasdaq Biotechnology Index has since increased roughly 36%.

Data compiled by Raymond James show that healthcare and biotechnology-focused mutual funds and exchange-traded funds registered net withdrawals of $1.5 billion for the week ending Wednesday. That amount represents a 1.53% contraction in assets under management for the group, covering 130 funds with combined assets near $99.5 billion.

The sector has now seen outflows in two consecutive weeks. On a year-to-date basis, net redemptions have accumulated to $1.98 billion.

Raymond James also reported movement in the breadth ratio, a measure defined as the number of funds recording inflows divided by the number seeing outflows. The ratio climbed to 0.48 from 0.45 the week before. The research note highlighted a historical observation: when the breadth ratio reaches 0.3, the biotech sector has, on average, rallied by 17.5% over the subsequent six months.

Separately noted by Raymond James, the breadth ratio stood at 0.28 on July 16. Since that mid-July reading, the Nasdaq Biotechnology Index has advanced by roughly 36%.

Taken together, the weekly flows and breadth metrics outline a picture of ongoing capital movement away from biotech-focused funds this week, set against a backdrop of prior breadth readings and subsequent index performance cited by the firm. The dataset covers 130 specialized funds and is expressed in both dollar flows and percentage change against the group's approximate $99.5 billion in assets.


Context and limitations

The figures presented are limited to the scope and timeframe reported by Raymond James - specifically the week ending Wednesday and year-to-date totals. The breadth ratio referenced is calculated as inflow-count divided by outflow-count among the funds in the sample, per the firm's definition. The note also cites a historical average gain associated with a breadth ratio threshold and provides a single prior ratio reading (0.28 on July 16) and the corresponding subsequent performance of the Nasdaq Biotechnology Index (about 36% increase since that date).

What the numbers show

  • Net outflows of $1.5 billion for the latest week covering healthcare and biotech mutual funds and ETFs.
  • Outflows equal a 1.53% decline in assets across 130 funds managing about $99.5 billion.
  • Year-to-date net outflows totaling $1.98 billion and two consecutive weeks of outflows.
  • Breadth ratio increased to 0.48 from 0.45, with historical context noted by Raymond James about rallies tied to low breadth readings and a past breadth reading of 0.28 on July 16.

Risks

  • Continued outflows may persist - the sector experienced outflows for a second consecutive week, which could further pressure fund assets and manager positioning (impacts: healthcare funds, biotech ETFs).
  • Breadth ratio interpretations have limits - while Raymond James cites historical average gains associated with a 0.3 threshold, past relationships do not guarantee future outcomes and the article does not provide predictive certainty (impacts: investor expectations in biotech/healthcare).
  • Data scope is bounded to the reported sample and timeframe - the numbers reflect the 130 funds and the week ending Wednesday, so broader market or longer-term dynamics are not covered in the figures provided (impacts: market analysts and allocators relying on this dataset).

More from Stock Markets

JPMorgan Raises Freshpet to Overweight, Says Competitive Concerns Are Overstated May 7, 2026 ASML Poised to Capitalize on Strong Low-NA EUV Demand as High-NA Adoption Lags May 7, 2026 SoftBank in Talks with Nvidia and Foxconn to Develop Japan-Made AI Servers May 7, 2026 Goldman Sachs Sees Modest Job Gains in April, Forecasts 75,000 Payroll Increase May 7, 2026 Bank of America Sees April Headline CPI Rising 0.5% as Energy Prices Surge May 7, 2026